Abstract: A recent Korean report showed that two patients with viral breakthrough during treatment with TDF-containing regimens were found to carry five
reverse transcriptase (
rt) mutations ([
rt]S106C[C],
rtH126Y[Y],
rtD134E[E],
rtM204I/V, and
rtL269I [I]), with the C, Y, E, and I mutations being associated with tenofovir resistance.